Grace Therapeutics Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine

Reuters

Aug 14, 2025

<a href="https://laohu8.com/S/GRCE">Grace Therapeutics</a> Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine

Grace Therapeutics Inc. has released a corporate presentation detailing the development of GTx-104, a novel intravenous form of nimodipine. This treatment is positioned to address significant unmet needs in the management of aneurysmal Subarachnoid Hemorrhage (aSAH) by potentially displacing the current oral standard of care. The pivotal Phase 3 STRIVE-ON safety trial for GTx-104 has successfully met its primary endpoint, showing clinical benefits over oral nimodipine. With Orphan Drug Status, the drug is set to receive seven-year market exclusivity, complemented by multi-layered intellectual property protection. A New Drug Application was submitted in June 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief on August 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2559861709"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559861709\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559861709?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 03:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559861709","market":"nz","top_or_hot":-1,"title":"Grace Therapeutics Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GRCE\">Grace Therapeutics</a> Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grace <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has released a corporate presentation detailing the development of GTx-104, a novel intravenous form of nimodipine. This treatment is positioned to address significant unmet needs in the management of aneurysmal Subarachnoid Hemorrhage (aSAH) by potentially displacing the current oral standard of care. The pivotal Phase 3 STRIVE-ON safety trial for GTx-104 has successfully met its primary endpoint, showing clinical benefits over oral nimodipine. With Orphan Drug Status, the drug is set to receive seven-year market exclusivity, complemented by multi-layered intellectual property protection. A New Drug Application was submitted in June 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grace Therapeutics Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrace Therapeutics Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-14 03:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GRCE\">Grace Therapeutics</a> Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grace <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has released a corporate presentation detailing the development of GTx-104, a novel intravenous form of nimodipine. This treatment is positioned to address significant unmet needs in the management of aneurysmal Subarachnoid Hemorrhage (aSAH) by potentially displacing the current oral standard of care. The pivotal Phase 3 STRIVE-ON safety trial for GTx-104 has successfully met its primary endpoint, showing clinical benefits over oral nimodipine. With Orphan Drug Status, the drug is set to receive seven-year market exclusivity, complemented by multi-layered intellectual property protection. A New Drug Application was submitted in June 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL85xpR2:1","article_id":"2559861709","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559861709","pubTimestamp":1755112471,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Grace Therapeutics Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine. Grace Therapeutics Inc. has released a corporate presentation detailing the development of GTx-104, a novel intravenous form of nimodipine. This treatment is positioned to address significant unmet needs in the management of aneurysmal Subarachnoid Hemorrhage  by potentially displacing the current oral standard of care. The pivotal Phase 3 STRIVE-ON safety trial for GTx-104 has successfully met its primary endpoint, showing clinical benefits over oral nimodipine. With Orphan Drug Status, the drug is set to receive seven-year market exclusivity, complemented by multi-layered intellectual property protection. A New Drug Application was submitted in June 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","GRCE":"GRACE THERAPEUTICS INC"},"translate_title":"Grace Therapeutics Inc.推出GTx-104通过静脉注射尼莫地平彻底改变aSAH治疗的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRCE":0.9},"content_text":"Grace Therapeutics Inc. Unveils Presentation on GTx-104's Potential to Revolutionize aSAH Treatment with Intravenous Nimodipine\n    \n\n        Grace Therapeutics Inc. has released a corporate presentation detailing the development of GTx-104, a novel intravenous form of nimodipine. This treatment is positioned to address significant unmet needs in the management of aneurysmal Subarachnoid Hemorrhage (aSAH) by potentially displacing the current oral standard of care. The pivotal Phase 3 STRIVE-ON safety trial for GTx-104 has successfully met its primary endpoint, showing clinical benefits over oral nimodipine. With Orphan Drug Status, the drug is set to receive seven-year market exclusivity, complemented by multi-layered intellectual property protection. A New Drug Application was submitted in June 2025. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief on August 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}